+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Antibody Contract Manufacturing Market, 2020 - 2030

  • PDF Icon

    Report

  • 305 Pages
  • January 2020
  • Region: Global
  • Roots Analysis
  • ID: 5008087
Description Jump to:

Overview

Since the approval of Orthoclone OKT3® in 1986, monoclonal antibodies have become an important part of modern healthcare practices. In fact, several experts consider monoclonal antibodies to be the backbone of the biopharmaceutical industry. It is worth noting that, till date, more than 100 therapeutic monoclonal antibodies have been approved across different geographies; recent approvals include (in reverse chronological order) Adakveo® (November 2019), Beovu® (October 2019), SKYRIZI™ (April 2019) and EVENITY™ (April 2019). Owing to their high specificity and the favorable safety profile associated with the therapeutic use of such molecules, antibody based interventions presently constitute the largest class of biologics in the industry.

This trend is unlikely to change in the near future as advanced variants, such as bispecific antibodies and antibody fragments-based products, are steadily gaining traction. Further, owing to legacy challenges associated with the development and production of biologics, such as advanced supply chain requirements, outsourcing antibody production operations is a popular trend.

The antibody contract manufacturing market is highly competitive, featuring companies of all sizes, some of which claim to offer end-to-end solutions, ranging from antibody development to commercial production. Historical and prevalent trends suggest that sponsor companies are likely to continue relying on contract service providers for various aspects of antibody-based product development and manufacturing. This dependence on outsourcing can be attributed to the high cost and time investment required to establish the necessary infrastructure and expertise in biologics.

The competition among contract manufacturing organizations (CMOs) engaged in this domain is high, with the availability of cutting-edge tools and technologies being one of the key differentiating factors that grant a competitive advantage over other players. Therefore, in order to establish a strong foothold in the market and also meet the growing demand for antibody therapeutics / reagents, CMOs are actively expanding their capacities and capabilities.

Scope of the Report

The "Antibody Contract Manufacturing Market, 2020-2030" report features an extensive study of the current market landscape and future opportunities associated with the contract manufacturing of antibodies.

The study also features a detailed analysis of key drivers and trends related to this evolving domain. Amongst other elements, the report includes:


  • A detailed review of the overall landscape of companies, offering contract services for the manufacturing of antibodies, along with information on year of establishment, company size, scale of operation (preclinical, clinical and commercial), location of headquarters, number of manufacturing facilities and location of these facilities, type of antibody manufactured (monoclonal antibodies, bispecific antibodies and polyclonal antibodies), type of expression systems used (mammalian, microbial and others), fill / finish operations and affiliations to regulatory agencies.
  • A competitiveness analysis of key players engaged in this domain, featuring an assessment based on their supplier strength (related to the experience of a contract manufacturer), and service strength (which takes into account the size of service portfolio and scale of operation).
  • A benchmark analysis, highlighting the key focus areas of small, mid-sized and large companies, comparing their existing capabilities within and beyond their respective (geography-based) peer groups.
  • An analysis of the various partnerships pertaining to contract manufacturing of antibodies, which have been established since 2013, based on several parameters, such as the year of agreement, type of partnership, project scale and focus therapeutic area.
  • An analysis of the various expansion initiatives undertaken by service providers, in order to augment their respective antibody manufacturing capabilities, over the period 2017-2019 (till October), taking into consideration parameters, such as year of expansion, type of expansion (capacity expansion, facility expansion and new facility), type of antibodies manufactured and location of manufacturing facility.
  • An estimate of the overall, installed capacity for manufacturing antibodies based on data reported by industry stakeholders in the public domain; it highlights the distribution of available antibody production capacity on the basis of company size (small, mid-sized, large and very large firms), scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia).
  • Informed estimates of the annual commercial and clinical demand for antibodies, based on various relevant parameters, such as target patient population, dosing frequency and dose strength.
  • Elaborate profiles of the key industry players that offer contract manufacturing services at all scales of operation and have more than two manufacturing facilities. Each profile features a brief overview of the company, information on its service portfolio, details related to its manufacturing capabilities and facilities, and an informed future outlook.  
  • A case study comparing the key characteristics of large molecule and small molecule drugs, along with details on the various steps and challenges involved in their respective manufacturing processes.
  • A discussion on affiliated trends, key drivers and challenges, under a SWOT framework, which are likely to impact the industry’s evolution, including a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall pharmaceutical industry.

One of the key objectives of the report was to estimate the existing market size and the future growth potential within the antibody contract manufacturing market. Based on multiple parameters, such as projected growth of overall antibody-based products market, cost of goods sold and direct manufacturing costs, we have developed informed estimates on the financial evolution of the market over the period 2020-2030. The report also provides details on the likely distribution of the current and forecasted opportunity across [A] type of antibodies (monoclonal antibodies, bispecific antibodies and others), [B] company size (small, mid-sized and large / very large), [C] scale of operation (preclinical / clinical and commercial), [E] expression systems (mammalian, microbial and others), and [F] key geographical regions (North America, Europe, Asia). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders in this domain.

The report features detailed transcripts of interviews held with the following individuals:


  • Dietmar Katinger, Chief Executive Officer, Polymun Scientific
  • David C Cunningham, Director Corporate Development, Goodwin Biotechnology   
  • Claire Otjes, Assistant Marketing Manager, Batavia Biosciences

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.


Table of Contents

1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Concept of an Antibody
3.3. Structure of an Antibody
3.4. Antibody Isotypes
3.5. Mechanism of Action of Antibodies
3.6. Types of Antibodies
3.6.1. Monoclonal Antibodies
3.6.2. Bispecific Antibodies
3.6.3. Polyclonal Antibodies
3.7. Overview of Contract Manufacturing
3.8. Need for Outsourcing in the Biopharmaceutical Industry
3.9. Advantages of Outsourcing Manufacturing Services
4. MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Antibody Contract Manufacturers: Overall Market Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Scale of Operation
4.2.4. Analysis by Location of Headquarters
4.2.5. Analysis by Location of Manufacturing Facilities
4.2.6. Analysis by Type of Antibodies Manufactured
4.2.7. Analysis by Expression Systems Used
4.2.8. Analysis by Fill / Finish Services Offered
4.2.9. Analysis by Regulatory Accreditations / Certifications
5. COMPANY COMPETITIVE ANALYSIS
5.1. Chapter Overview
5.2. Assumptions and Key Input Parameters
5.3. Methodology
5.4. Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
5.5. Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
5.6. Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. AGC Biologics
6.2.1. Company Overview
6.2.2. Service Portfolio
6.2.3. Manufacturing Facilities and Capabilities
6.2.4. Future Outlook
6.3. Aldevron
6.3.1. Company Overview
6.3.2. Service Portfolio
6.3.3. Manufacturing Facilities and Capabilities
6.3.4. Future Outlook
6.4. BioXcellence (Boehringer Ingelheim)
6.4.1. Company Overview
6.4.2. Service Portfolio
6.4.3. Manufacturing Facilities and Capabilities
6.4.4. Future Outlook
6.5. FUJIFILM Diosynth Biotechnologies
6.5.1. Company Overview
6.5.2. Service Portfolio
6.5.3. Manufacturing Facilities and Capabilities
6.5.4. Future Outlook
6.6. Lonza
6.6.1. Company Overview
6.6.2. Service Portfolio
6.6.3. Manufacturing Facilities and Capabilities
6.6.4. Future Outlook
6.7. Merck
6.7.1. Company Overview
6.7.2. Service Portfolio
6.7.3. Manufacturing Facilities and Capabilities
6.7.4. Future Outlook
6.8. Novasep
6.8.1. Company Overview
6.8.2. Service Portfolio
6.8.3. Manufacturing Facilities and Capabilities
6.8.4. Future Outlook
6.9. Samsung BioLogics
6.9.1. Company Overview
6.9.2. Service Portfolio
6.9.3. Manufacturing Facilities and Capabilities
6.9.4. Future Outlook
6.10. Synthon
6.10.1. Company Overview
6.10.2. Service Portfolio
6.10.3. Manufacturing Facilities and Capabilities
6.10.4. Future Outlook
7. CASE STUDY: COMPARISON OF SMALL AND LARGE MOLECULES (BIOLOGICS) DRUGS / THERAPIES
7.1. Chapter Overview
7.2. Small Molecule Drugs and Biologics
7.2.1. Comparison of Strengths and Weakness of Small Molecules and Biologics
7.2.2. Comparison of Key Specifications
7.2.3. Comparison of Manufacturing Processes
7.2.4. Comparison of Key Manufacturing-related Challenges
8. BENCHMARK ANALYSIS
8.1. Chapter Overview
8.2. Methodology
8.3. Region-wise Benchmarking
8.3.1. North America, Peer Group I
8.3.2. North America, Peer Group II
8.3.3. North America, Peer Group III
8.3.4. Europe, Peer Group IV
8.3.5. Europe, Peer Group V
8.3.6. Europe, Peer Group VI
8.3.7. Asia, Peer Group VII
8.3.8. Asia, Peer Group VIII
8.4. Concluding Remarks
9. PARTNERSHIPS
9.1. Chapter Overview
9.2. Partnerships Models
9.3. Antibody Contract Manufacturing: List of Partnerships
9.3.1. Analysis by Year of Partnership
9.3.2. Analysis by Type of Partnership
9.3.3. Analysis by Year and Type of Partnership
9.3.4. Analysis by Type of Antibody
9.3.5. Analysis by Project Scale
9.3.6. Analysis by Focus Therapeutic Area
9.3.7. Most Active Players: Analysis by Number of Partnerships and Type of Partnership
9.3.8. Geographical Analysis
9.3.8.1. Continent-wise Distribution
9.3.8.2. Country-wise Distribution
10. RECENT EXPANSIONS
10.1. Chapter Overview
10.2. Antibody Contract Manufacturers: List of Expansions
10.2.1. Analysis by Year of Expansion
10.2.2. Analysis by Type of Expansion
10.2.3. Analysis by Type of Antibody
10.2.4. Analysis by Location of Manufacturing Facility
10.2.5. Analysis by Location of Manufacturing Facility and Type of Expansion
10.2.6. Analysis of Most Active Players by Number of Expansions
10.2.7. Geographical Analysis
10.2.7.1. Country-wise Distribution
11. CAPACITY ANALYSIS
11.1. Chapter Overview
11.2. Assumptions and Methodology
11.3. Antibody Contract Manufacturers: Installed Global Capacity
11.3.1. Analysis by Company Size
11.3.2. Analysis by Scale of Operation
11.3.3. Analysis by Location of Manufacturing Facility
11.4. Concluding Remarks
12. DEMAND ANALYSIS
12.1 Chapter Overview
12.2 Assumptions and Methodology
12.3 Antibody Contract Manufacturing Market: Overall Annual Demand
12.3.1. Analysis by Scale of Operation
12.3.2. Analysis by Geography
13. MARKET SIZING AND OPPORTUNITY ANALYSIS
13.1. Chapter Overview
13.2. Assumptions and Forecast Methodology
13.3. Overall Antibody Contract Manufacturing Market, 2020-2030
13.4. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody
13.5. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size
13.6. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation
13.7. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used
13.8. Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography
13.8.1. Antibody Contract Manufacturing Market in North America, 2020-2030
13.8.1.1. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies
13.8.1.2. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies
13.8.1.3. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies
13.8.1.4. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.1.5. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations
13.8.1.6. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations
13.8.1.7. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations
13.8.1.8. Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations
13.8.2. Antibody Contract Manufacturing Market in Europe, 2020-2030
13.8.2.1. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies
13.8.2.2. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies
13.8.2.3. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies
13.8.2.4. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.2.5. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations
13.8.2.6. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations
13.8.2.7. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations
13.8.2.8. Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations
13.8.3. Antibody Contract Manufacturing Market in Asia, 2020-2030
13.8.3.1. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies
13.8.3.2. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies
13.8.3.3. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies
13.8.3.4. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations
13.8.3.5. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations
13.8.3.6. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations
13.8.3.7. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations
13.8.3.8. Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations
14. SWOT ANALYSIS
14.1. Chapter Overview
14.2. Strengths
14.3. Weaknesses
14.4. Opportunities
14.5. Threats
14.6. Comparison of SWOT Factors
14.7. Concluding Remarks
15. FUTURE OF THE ANTIBODY CMO MARKET
15.1. Chapter Overview
15.2. Outsourcing Activity Anticipated to Witness Significant Growth
15.3. Shift from One-time Contractual Engagements to Strategic Partnerships
15.4. Adoption of New and Innovative Technologies
15.5. Concluding Remarks
16. INTERVIEW TRANSCRIPTS
16.1. Chapter Overview
16.2. Dietmar Katinger, Chief Executive Officer, Polymun Scientific
16.3. David C Cunningham, Director Corporate Development, Goodwin Biotechnology
16.4. Birgit Schwab, Senior Manager Strategic Marketing, Rentschler Biopharma
16.5. Claire Otjes, Assistant Marketing Manager, Batavia Biosciences
17. APPENDIX 1: LIST OF ANTIBODY CUSTOM MANUFACTURERS18. APPENDIX 2: TABULATED DATA19. APPENDIX 3: LIST OF COMPANIES AND ORGANIZATIONS
List Of Figures
Figure 3.1 Historical Milestones Related to the Discovery of Antibodies
Figure 3.2 Structure of an Antibody
Figure 3.3 Mechanism of Action of Antibodies
Figure 3.4 Monoclonal Antibody Production
Figure 3.5 Symmetric and Asymmetric Bispecific Antibodies
Figure 3.6 Mechanism of Action of Bispecific Antibodies
Figure 3.7 Polyclonal Antibody Production
Figure 3.8 Applications of Polyclonal Antibodies
Figure 3.9 Types of Third Party Service Providers
Figure 4.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Figure 4.2 Antibody Contract Manufacturers: Distribution by Company Size
Figure 4.3 Antibody Contract Manufacturers: Distribution by Scale of Operation
Figure 4.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Figure 4.5 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Figure 4.6 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Figure 4.7 Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
Figure 4.8 Antibody Contract Manufacturers: Distribution by Expression Systems Used
Figure 4.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Figure 4.10 Antibody Contract Manufacturers: Distribution by Regulatory Accreditations / Certifications
Figure 5.1 Company Competitiveness Analysis: Antibody Contract Manufacturers in North America
Figure 5.2 Company Competitiveness Analysis: Antibody Contract Manufacturers in Europe
Figure 5.3 Company Competitiveness Analysis: Antibody Contract Manufacturers in Asia
Figure 6.1 AGC Biologics: Service Portfolio
Figure 6.2 Aldevron: Service Portfolio
Figure 6.3 BioXcellence (Boehringer Ingelheim): Service Portfolio
Figure 6.4 FUJIFILM Diosynth Biotechnologies: Service Portfolio
Figure 6.5 Lonza: Service Portfolio
Figure 6.6 Merck: Service Portfolio
Figure 6.7 Novasep: Service Portfolio
Figure 6.8 Samsung BioLogics: Service Portfolio
Figure 6.9 Synthon: Service Portfolio
Figure 7.1 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019 (till August)
Figure 7.2 Comparison of Key Characteristics of Small Molecules and Biologics
Figure 7.3 Comparison of Manufacturing Processes of Small Molecules and Biologics
Figure 8.1 Benchmark Analysis: Distribution by Region and Company Size
Figure 8.2 Benchmark Analysis: North America, Peer Group I
Figure 8.3 Benchmark Analysis: North America, Peer Group II
Figure 8.4 Benchmark Analysis: North America, Peer Group III
Figure 8.5 Benchmark Analysis: Europe, Peer Group IV
Figure 8.6 Benchmark Analysis: Europe, Peer Group V
Figure 8.7 Benchmark Analysis: Europe, Peer Group VI
Figure 8.8 Benchmark Analysis: Asia, Peer Group VII
Figure 8.9 Benchmark Analysis: Asia, Peer Group VIII
Figure 8.10 Benchmark Analysis: Comparison of Services and Capabilities across Different Peer Groups
Figure 9.1 Partnerships: Distribution by Year of Partnership
Figure 9.2 Partnerships: Distribution by Type of Partnership
Figure 9.3 Partnerships: Distribution by Year and Type of Partnership
Figure 9.4 Partnerships: Distribution by Type of Antibody
Figure 9.5 Partnerships: Distribution by Project Scale
Figure 9.6 Partnerships: Distribution by Focus Therapeutic Area
Figure 9.7 Partnerships: Most Active Players
Figure 9.8 Partnerships: Country-wise Distribution
Figure 9.9 Partnerships: Continent-wise Distribution
Figure 10.1 Recent Expansions: Distribution by Year of Expansion
Figure 10.2 Recent Expansions: Distribution by Type of Expansion
Figure 10.3 Recent Expansions: Distribution by Type of Antibody
Figure 10.4 Recent Expansions: Distribution by Type of Antibody and Expansion
Figure 10.5 Recent Expansions: Distribution by Location of Facility (Region-wise)
Figure 10.6 Recent Expansions: Distribution by Location of Facility (Country-wise)
Figure 10.7 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Figure 10.8 Recent Expansions: Most Active Players
Figure 10.9 Recent Expansions: Distribution by Local and International Expansions
Figure 11.1. Antibody Contract Manufacturing: Installed Global Capacity
Figure 11.2. Antibody Contract Manufacturing Capacity: Distribution by Company Size
Figure 11.3. Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
Figure 11.4. Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Figure 12.1 Demand Analysis: Annual Demand for Antibodies
Figure 12.2 Demand Analysis: Annual Demand for Clinical Scale Operations
Figure 12.3 Demand Analysis: Annual Demand for Commercial Scale Operations
Figure 12.4 Demand Analysis: Annual Demand in North America
Figure 12.5 Demand Analysis: Annual Demand in Europe
Figure 12.6 Demand Analysis: Annual Demand in Asia
Figure 13.1 Overall Antibody Contract Manufacturing Market, 2020-2030
Figure 13.2 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody (USD Billion)
Figure 13.3 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Figure 13.4 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Figure 13.5 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used (USD Billion)
Figure 13.6 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Figure 13.7 Antibody Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Figure 13.8 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.9 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.10 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.11 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.12 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.13 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.14 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.15 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 13.16 Antibody Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Figure 13.17 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.18 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.19 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.20 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.21 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.22 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.23 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.24 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 13.25 Antibody Contract Manufacturing Market in Asia, 2020-2030 (USD Billion)
Figure 13.26 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies (USD Billion)
Figure 13.27 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies (USD Billion)
Figure 13.28 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Figure 13.29 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Figure 13.30 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Figure 13.31 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Figure 13.32 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Figure 13.33 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Figure 14.1 Antibody Contract Manufacturing: SWOT Analysis
Figure 14.2 Comparison of SWOT Factors: Harvey Ball Analysis
List Of Tables
Table 3.1 Key Features of Antibody Isotypes
Table 3.2 Mechanism of Action of Therapeutic Antibodies against Important Target Classes
Table 3.3 List of Approved Monoclonal Antibodies
Table 3.4 Differences between Monoclonal and Polyclonal Antibodies
Table 4.1 List of Antibody Contract Manufacturers
Table 4.2 Antibody Contract Manufacturers: Information on Type of Antibodies Manufactured
Table 4.3 Antibody Contract Manufacturers: Information on Scale of Operation
Table 4.4 Antibody Contract Manufacturers: Information on Expression Systems Used
Table 4.5 Antibody Contract Manufacturers: Information on Fill / Finish Services Offered
Table 4.6 Antibody Contract Manufacturers: Information on Regulatory Accreditations / Certifications
Table 6.1 AGC Biologics: Company Overview
Table 6.2 AGC Biologics: Overview of Manufacturing Capabilities
Table 6.3 AGC Biologics: Future Outlook
Table 6.4 Aldevron: Company Overview
Table 6.5 Aldevron: Overview of Manufacturing Capabilities
Table 6.6 Aldevron: Future Outlook
Table 6.7 BioXcellence (Boehringer Ingelheim): Company Overview
Table 6.8 BioXcellence (Boehringer Ingelheim): Overview of Manufacturing Capabilities
Table 6.9 BioXcellence (Boehringer Ingelheim): Future Outlook
Table 6.10 FUJIFILM Diosynth Biotechnologies: Company Overview
Table 6.11 FUJIFILM Diosynth Biotechnologies: Overview of Manufacturing Capabilities
Table 6.12 FUJIFILM Diosynth Biotechnologies: Future Outlook
Table 6.13 Lonza: Company Overview
Table 6.14 Lonza: Overview of Manufacturing Capabilities
Table 6.15 Lonza: Future Outlook
Table 6.16 Merck: Company Overview
Table 6.17 Merck: Overview of Manufacturing Capabilities
Table 6.18 Merck: Future Outlook
Table 6.19 Novasep: Company Overview
Table 6.20 Novasep: Overview of Manufacturing Capabilities
Table 6.21 Novasep: Future Outlook
Table 6.22 Samsung BioLogics: Company Overview
Table 6.23 Samsung BioLogics: Overview of Manufacturing Capabilities
Table 6.24 Samsung BioLogics: Future Outlook
Table 6.25 Synthon: Company Overview
Table 6.26 Synthon: Overview of Manufacturing Capabilities
Table 6.27 Synthon: Future Outlook
Table 7.1 Comparison of Strengths and Weaknesses of Small Molecules and Biologics
Table 7.2 Comparison of Development Characteristics of Small Molecules and Biologics
Table 8.1 Benchmark Analysis: Peer Groups
Table 9.1 Antibody Contract Manufacturing: List of Partnerships, 2013-2019
Table 9.2 Antibody Contract Manufacturing Partnerships: Information on Type of Antibodies, Project Scale and Therapeutic Area
Table 10.1 Antibody Contract Manufacturing: List of Expansions, 2017-2019
Table 10.2 Antibody Contract Manufacturing Expansions: Information on Type of Antibodies
Table 14.1 Patent Approval Information of Best-selling Biologics
Table 17.1 Antibody Contract Manufacturers: Distribution by Year of Establishment
Table 17.2 Antibody Contract Manufacturers: Distribution by Company Size
Table 17.3 Antibody Contract Manufacturers: Distribution by Scale of Operation
Table 17.4 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Region-wise)
Table 17.5 Antibody Contract Manufacturers: Distribution by Location of Headquarters (Country-wise)
Table 17.6 Antibody Contract Manufacturers: Distribution by Location of Manufacturing Facilities
Table 17.7 Antibody Contract Manufacturers: Distribution by Type of Antibodies Manufactured
Table 17.8 Antibody Contract Manufacturers: Distribution by Expression Systems Used
Table 17.9 Antibody Contract Manufacturers: Distribution by Fill / Finish Services Offered
Table 17.10 Antibody Contract Manufacturers: Distribution by Regulatory Accreditations /
Table 17.11 Small Molecules and Biologics: Historical Trend of FDA Approval, 2010-2019 (till August)
Table 17.12 Partnerships: Distribution by Year of Partnership
Table 17.13 Partnerships: Distribution by Type of Partnership
Table 17.14 Partnerships: Distribution by Year and Type of Partnership
Table 17.15 Partnerships: Distribution by Type of Antibody
Table 17.16 Partnerships: Distribution by Project Scale
Table 17.17 Partnerships: Distribution by Focus Therapeutic Area
Table 17.18 Partnerships: Most Active Players
Table 17.19 Partnerships: Country-wise Distribution
Table 17.20 Recent Expansions: Distribution by Year of Expansion
Table 17.21 Recent Expansions: Distribution by Type of Expansion
Table 17.22 Recent Expansions: Distribution by Type of Antibody
Table 17.23 Recent Expansions: Distribution by Type of Antibody and Expansion
Table 17.24 Recent Expansions: Distribution by Location of Facility (Region-wise)
Table 17.25 Recent Expansions: Distribution by Location of Facility (Country-wise)
Table 17.26 Recent Expansions: Distribution by Location of Manufacturing Facility and Type of Expansion
Table 17.27 Recent Expansions: Most Active Players
Table 17.28 Recent Expansions: Distribution by Local and International Expansions
Table 17.29 Antibody Contract Manufacturing: Installed Global Capacity
Table 17.30 Antibody Contract Manufacturing Capacity: Distribution by Company Size
Table 17.31 Antibody Contract Manufacturing Capacity: Distribution by Scale of Operation
Table 17.32 Antibody Contract Manufacturing Capacity: Distribution by Location of Manufacturing Facility
Table 17.33 Demand Analysis: Annual Demand for Antibodies
Table 17.34 Demand Analysis: Annual Demand for Clinical Scale Operations
Table 17.35 Demand Analysis: Annual Demand for Commercial Scale Operations
Table 17.36 Demand Analysis: Annual Demand in North America
Table 17.37 Demand Analysis: Annual Demand in Europe
Table 17.38 Demand Analysis: Annual Demand in Asia
Table 17.39 Overall Antibody Contract Manufacturing Market, 2020-2030
Table 17.40 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Type of Antibody (USD Billion)
Table 17.41 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Company Size (USD Billion)
Table 17.42 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Scale of Operation (USD Billion)
Table 17.43 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Expression System Used (USD Billion)
Table 17.44 Antibody Contract Manufacturing Market, 2020-2030: Distribution by Geography (USD Billion)
Table 17.45 Antibody Contract Manufacturing Market in North America, 2020-2030 (USD Billion)
Table 17.46 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Small Companies (USD Billion)
Table 17.47 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.48 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.49 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.50 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.51 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.52 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.53 Antibody Contract Manufacturing Market in North America, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Table 17.54 Antibody Contract Manufacturing Market in Europe, 2020-2030 (USD Billion)
Table 17.55 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Small Companies (USD Billion)
Table 17.56 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.57 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.58 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.59 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.60 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.61 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.62 Antibody Contract Manufacturing Market in Europe, 2020-2030: Share of Other Expression System-based Operations (USD Billion)
Table 17.63 Antibody Contract Manufacturing Market in Asia, 2020-2030 (USD Billion)
Table 17.64 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Small Companies (USD Billion)
Table 17.65 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mid-sized Companies (USD Billion)
Table 17.66 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Large / Very Large Companies (USD Billion)
Table 17.67 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Preclinical / Clinical Scale Operations (USD Billion)
Table 17.68 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Commercial Scale Operations (USD Billion)
Table 17.69 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Mammalian Cell-based Operations (USD Billion)
Table 17.70 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Microbial Cell-based Operations (USD Billion)
Table 17.71 Antibody Contract Manufacturing Market in Asia, 2020-2030: Share of Other Expression System-based Operations (USD Billion)

Companies Mentioned

  • AbbVie Contract Manufacturing
  • Abcuro
  • Abdi Ibrahim
  • A-Bio Pharma
  • ABL
  • ABL Bio
  • Absolute Antibody
  • Abzena
  • AC Immune
  • Acticor Biotech
  • Actinium Pharmaceuticals
  • Adagene
  • Affinita Biotech
  • Affinity Life Sciences
  • AGC Biologics
  • Ajinomoto Althea
  • Alcami
  • Aldevron
  • Alethia Biotherapeutics
  • Allele Biotechnology & Pharmaceuticals
  • Alligator Bioscience
  • Alvotech
  • Annular Biotech
  • Antibodies Incorporated
  • Antibody Production Services (division of Life Science Group)
  • Arabio
  • Arcus Biosciences
  • argenx
  • ASKA Biotech
  • ASLAN Pharmaceuticals
  • AURA Biotechnologies
  • AutekBio
  • Avid Bioservices
  • Avioq
  • Axcellerate Pharma
  • Batavia Biosciences
  • Baxter BioPharma Solutions
  • Bayer
  • Baylor Scott & White Research Institute
  • BeiGene
  • Bharat Serums and Vaccine
  • BIBITEC
  • BINEX
  • BioInvent International
  • BioLineRx
  • Biomay
  • Biomedical Advanced Research and Development Authority (BARDA)
  • BiosanaPharma
  • Biosynergy EUROPE
  • BioTechnique
  • Biovian
  • BioVolutions
  • BioXcellence (Boehringer Ingelheim)
  • BJ Bioscience
  • Brii Biosciences
  • Bristol-Myers Squibb
  • Bruker
  • Calypso Biotech
  • CANbridge
  • Capralogics
  • Catalent
  • Catalent Biologics
  • Cell Culture Company
  • Cell Essentials
  • Celonic
  • Center of iPS Cell Research and Application, Kyoto University
  • Cerbios-Pharma
  • Changchun High & New Technology Industry
  • ChemPartner
  • Chiome Bioscience
  • CinnaGen
  • Citryll
  • CMAB Biopharma
  • CMC Biologics
  • Cobra Biologics
  • Compugen
  • Cook Pharmica
  • Creative Biolabs
  • CytoDyn
  • Cytovance® Biologics
  • DaTaMabs
  • Diatec Monoclonals
  • DM Bio
  • Dyax
  • Effimune
  • EirGenix
  • Emergent BioSolutions
  • Enzene Biosciences
  • Etinpro
  • EuBiologics
  • Eurofins CDMO
  • Eurogentec
  • exonbio
  • FairJourney Biologics
  • Faron Pharmaceuticals
  • Forty Seven
  • F-star
  • FUJIFILM Diosynth Biotechnologies
  • GlaxoSmithKline
  • Glenmark
  • Goodwin Biotechnology
  • GTP Technology
  • HALIX
  • Harbour BioMed
  • Hong Kong Institute of Biotechnology
  • Horizon Pharma
  • IBC Generium
  • IDT Biologika
  • I-Mab Biopharma
  • Immune Pharmaceuticals
  • Inno Biologics
  • InVivo Biotech
  • JHL Biotech
  • JSR
  • KBI Biopharma
  • Kemwell Biopharma
  • KUBio (a manufacturing unit of GE Healthcare)
  • LakePharma
  • LAMPIRE Biological Laboratories
  • Laureate Biopharmaceutical Services
  • LFB Biomanufacturing
  • Lipum
  • Lonza
  • Lupin
  • Mabion
  • MabPlex
  • MAbSilico
  • Mab-Venture Biopharma
  • MacroGenics
  • Maine Biotechnology Services
  • MassBiologics
  • Medicago
  • MedImmune
  • Medix Biochemica
  • Menarini Biotech
  • Merck
  • Meridian Life Science
  • Merus
  • Mologic
  • MorphoSys
  • Mycenax Biotech
  • Nitto Avecia Pharma Services
  • Northway Biotechpharma
  • Novasep
  • NovoCodex Biopharmaceuticals
  • Omeros
  • OncoQuest
  • OncoSynergy
  • OncoVent
  • OsoBio
  • Pall
  • Pamlico Biopharma
  • Paragon Bioservices (a unit of Catalent Biologics)
  • Particle Sciences (a Lubrizol Company)
  • Pharmedartis
  • Pierre Fabre
  • Pionyr Immunotherapeutics
  • Piramal Pharma Solutions
  • PMI BioPharma Solutions
  • Polymun Scientific
  • Powerway Biotech
  • Praxis Pharmaceutical
  • Precision Biologics
  • Premas Biotech
  • Prestige BioPharma
  • ProBioGen
  • PX'Therapeutics
  • Radimmune Therapeutics
  • ReliaTech
  • Rentschler Biopharma
  • Richter-Helm BioLogics
  • River Vision Development
  • RuiYi
  • Samsung BioLogics
  • Sandoz (a Novartis division)
  • Sanofi
  • SDIX
  • Selexis
  • Selexys Pharmaceuticals (acquired by Novartis)
  • Siam Bioscience
  • Siegfried
  • Sun Pharmaceutical
  • Surface Oncology
  • Suzhou Kintor Pharmaceuticals
  • Symbiosis Pharmaceutical Services
  • Symphogen
  • Syngene (a subsidiary of Biocon)
  • Synthelis
  • Synthon
  • Takara Bio
  • The Native Antigen
  • Therapure Biopharma (Therapure Biomanufacturing)
  • Thermo Fisher Scientific
  • Tizona Therapeutics
  • Tmunity Therapeutics
  • Toyobo Biologics
  • Translational Sciences
  • Trellis Bioscience
  • University College London
  • University of Toyama
  • Vibalogics
  • Vivoryon Therapeutics
  • Wacker Biotech
  • Waisman Biomanufacturing
  • WuXi AppTec
  • WuXi Biologics
  • Xpress Biologics
  • Zymeworks

Methodology

 

 

Loading
LOADING...

Related Topics

Related Reports

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions - Product Image

Global Biologics Contract Manufacturing (Biopharma CDMO/Biopharma CMO/Biologics Manufacturing) Market 2022-2035 by Type of Service(s) Offered, Type of Biologic Manufactured, Type of Expression System Used, Scale of Operation, Company Size, and Key Geographical Regions

  • Report
  • 799 Pages
  • Global
From
Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030 - Product Image

Global Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Forecast 2024-2030

  • Report
  • 193 Pages
  • Global
From
Antibody Contract Manufacturing Global Market Report 2024 - Product Image

Antibody Contract Manufacturing Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030 - Product Image

Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030

  • Report
  • 175 Pages
  • Global
From
Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034 - Product Image

Contract Manufacturing Outsourcing (CMO) of Sterile Injectable Drugs Market Report 2024-2034

  • Report
  • 428 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.